Posts by: Steve Bryson PhD

News, PH News

Infants with mild or severe forms of persistent pulmonary hypertension of the newborn, who were discharged from hospital, were significantly more likely to be readmitted or die within their ... Read more

September 26, 2019September 26, 2019

Significant Racial Variability Exists Among Subtypes and Survival in Children with PH, Study Says

News

Analysis of a North American pediatric registry revealed significant variability of pulmonary hypertension (PH) subtypes among children of different racial and ethnic groups, with reduced survival rates among black ... Read more

September 26, 2019September 26, 2019

Arterial Shunt for PAH Receives FDA’s Breakthrough Device Designation

News

V-Wave’s new interatrial shunt — a medical device designed to reduce arterial heart pressure — has been granted breakthrough device designation by the U.S. Food and Drug Administration (FDA) ... Read more

September 16, 2019September 18, 2019

Acceleron’s Sotatercept Receives FDA’s Orphan Drug Status for PAH

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to sotatercept for the treatment of pulmonary arterial hypertension (PAH), according to Acceleron Pharma, the therapy’s manufacturer. ... Read more

September 9, 2019September 11, 2019

Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals

News, PAH News

Only two non-invasive diagnostic tests are required to best predict the risk of adverse events in people with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH), a new study ... Read more

August 23, 2019August 28, 2019

Targeting Feedback Signaling Mechanism Involved in Vascular Remodeling May Prevent PH, Study Finds

News

Disrupting the vascular remodeling feedback signaling loop mediated by CD146-HIF-1α can effectively prevent the development of pulmonary hypertension (PH) in mice, a study found. This suggests that medicines that could ... Read more

August 8, 2019August 9, 2019

Interleukin-1 Receptor Antagonist Reduces PH in Newborn Mice, Study Finds

News, PH News

Blocking the protein interleukin-1 (IL-1) protects against pulmonary hypertension (PH) induced by complications from bronchopulmonary dysplasia (BPD) caused by high levels of oxygen, a new study in newborn mice ... Read more

Posts by: Steve Bryson PhD

Steve Bryson PhD

Infants with PPHN More Likely to be Readmitted to Hospital Within First Year, Study Reports

Significant Racial Variability Exists Among Subtypes and Survival in Children with PH, Study Says

Arterial Shunt for PAH Receives FDA’s Breakthrough Device Designation

Acceleron’s Sotatercept Receives FDA’s Orphan Drug Status for PAH

Two Non-Invasive Tests Predict PAH Prognosis in Patients with Congenital Heart Disease, Study Reveals

Targeting Feedback Signaling Mechanism Involved in Vascular Remodeling May Prevent PH, Study Finds

Interleukin-1 Receptor Antagonist Reduces PH in Newborn Mice, Study Finds

Pin It on Pinterest